David Nicholson

Despite Amazon.com Inc. (NASDAQ:AMZN) enduring its worst losing streak in two decades, Futurum Chief Research Officer David Nicholson argues the market's aggressive sell-off is driven by anxiety rather than a shift in business fundamentals. Market Sentiment Vs. Reality Amazon recently faced a...

Early Monday, Allergan plc Ordinary Shares (NYSE: AGN) — one of the world's largest pharmaceutical companies that produces branded and generic drugs, and performs pharmaceutical research and development — announced its recent acquisition of Zeltiq Aesthetics. Benzinga had the privilege...

Tobira Therapeutics Inc (NASDAQ: TBRA), a clinical-stage bio-pharmaceutical company that focuses on the development of therapies to treat non-alcoholic steatohepatitis (NASH) and other liver diseases, soared higher by more than 760 percent on Tuesday after the company agreed to sell itself to...

Historically, the U.S. Food and Drug Administration has not exactly been a “speed demon” when it comes to approving new drugs. Thanks to the Generating Antibiotics Incentives Now (GAIN) Act and forward-thinking companies like Actavis plc (NYSE: ACT) that are taking advantage of that...